Genmab A/S (GMAB) Set to Announce Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.36 per share and revenue of $1.20 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. On average, analysts expect Genmab A/S to post $1.22 EPS for the current fiscal year and $1.70 EPS for the next fiscal year.

Genmab A/S Price Performance

Genmab A/S stock traded up $0.95 during midday trading on Tuesday, reaching $55.87. 557,354 shares of the stock traded hands, compared to its average volume of 2,478,013. The stock has a market cap of $34.86 billion, a P/E ratio of 43.98, a PEG ratio of 2.47 and a beta of 0.81. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $59.97. The stock’s fifty day moving average is $37.55 and its 200-day moving average is $30.69. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GMAB shares. HC Wainwright upped their price target on shares of Genmab A/S from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Weiss Ratings raised Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Guggenheim increased their price objective on shares of Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. TD Cowen lifted their target price on Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Finally, New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and an average target price of $53.61.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.